|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2011-08-17 |
Open-label, Drug Interaction Study of Pyronaridine-artesunate and Metoprolol in Healthy Volunteers and Pyronaridine-artesunate Redosing Study in Healthy Volunteers
The primary objective of the drug-drug interaction study is to evaluate any drug interaction between the CYP2D6 substrate metoprolol and pyronaridine-artesunate in healthy volunteers.
The primary objective of the pyronaridine-artesunate redosing study is to determine the safety of redosing a 3-day regimen of pyronaridine-artesunate following 60 or 90 days in healthy volunteers.
A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry
The combination of pyronaridine and artesunate is an antimalarial therapy in development. This mass balance study is intended to determine the rate and extent of excretion of total radioactivity in urine and feces following administration of a single oral micro-dose of 14C-pyronaridine in humans.
Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers
The primary objective of the study is to determine any drug interaction between the antimalarial Pyramax (pyronaridine artesunate) and the protease inhibitor ritonavir in healthy subjects. The secondary objective of the study is to assess further the safety of Pyramax in this setting.
100 项与 Shin Poong Daewoo Pharma Co. Ltd. 相关的临床结果
0 项与 Shin Poong Daewoo Pharma Co. Ltd. 相关的专利(医药)
100 项与 Shin Poong Daewoo Pharma Co. Ltd. 相关的药物交易
100 项与 Shin Poong Daewoo Pharma Co. Ltd. 相关的转化医学